Olmesartan Medoxomil/Hctz Teva (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil/Hctz Teva, is a angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension, often in combination with a diuretic, and is prescribed for adults. GNH USA supplies Olmesartan Medoxomil/Hctz Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartan Medoxomil/Hctz Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan Medoxil/Hctz Teva is used in cardiovascular therapy, targeting blood‑pressure regulation pathways. - Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Heart failure adjunct: assists in fluid management when combined with other heart‑failure therapies. - Diabetic nephropathy protection: helps delay progression of kidney damage by controlling blood pressure. - Stroke prevention: contributes to secondary prevention by maintaining target blood‑pressure levels. - Chronic kidney disease management: used as part of a regimen to control hypertension in CKD patients.

Common Side Effects: - Dizziness  - Headache  - Fatigue  - Cough  - Increased urination  - Electrolyte imbalance (e.g., low potassium) Serious or Rare Side Effects: - Severe hypotension  - Acute kidney injury  - Hyperkalemia  - Angio‑angry  - Liver enzyme elevation  - Blood dyscrasias  - 

Olmesartan Medoxil/Hctz Teva is a 

-      t   t t t t t"""""""""""""""""""""""""""""""""""""""""""""""""""""""""""